Abstract
Since the reports of Goldfinger and Ozkan in 1972, colchicine remains the treatment of choice for FMF [1, 2]. Colchicine is an alkaloid extracted from the bulbs of a plant called Colchicum autumnale (meadow saffron). It was first recommended for the treatment of gout by the Greek physician Alexander of Tralles in the sixth century A.D. [3]. Subsequently, it has been employed for an increasing number of suggested and approved indications including primary biliary cirrhosis (PBC), alcohol-induced hepatitis, psoriasis, Behcet’s disease, Sweet’s syndrome, scleroderma, sarcoidosis, and amyloidosis. Perhaps the most effective results have been obtained in the prophylaxis of familial Mediterranean fever (FMF).
Keywords
- Primary Biliary Cirrhosis
- Familial Mediterranean Fever
- Disseminate Intravascular Coagulation
- Sperm Motility
- Colchicine Treatment
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Golfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.
Ozkan E, Okur O, Eekmekci A, et al. A new approach to the treatment of periodic fever. Med Bull Istanbul Med Fac. 1972;5:44–9.
Ben-Chetrit E, Levy N. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48–59.
Besis M, Breton-Gorius J. Rapports entre noyau et centrioles dans les granulocytes étalalés. Rúle des microtubules. Nouv Rev Fr Hematol. 1967;7:601–20.
Sackett DL, Varma JK. Molecular mechanism of colchicine action: induced local unfolding of b-tubulin. Biochemistry. 1993;32:13560–5.
Vandcandelaere A, Martin SR, Engelborghs Y. Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules. Biochem J. 1997;323:189–96.
Li Z, Davis GS, Mohr C. Inhibition of LPS induced tumor necrosis factor-a production by colchicine and other microtubules disrupting drugs. Immunobiology. 1996;195:624–9.
Ding AH, Porteu F, Sanchez E, Nathan CF. Down-regulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolarizing agents. J Exp Med. 1990;171:715–7.
Cronstein BN, Molad Y, Reiban J. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994–1002.
Paya M, Terencio MC, Ferrandiz ML, Alcaraz MJ. Involvement of secretory phospholipase A2 activity in the zymosan air pouch model of inflammation. Br J Pharmacol. 1996;117:1773–9.
Zurier RB, Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from human leukocytes: I, effect of cyclic nucleotides and colchicine. J Cell Biol. 1973;58:27–41.
Wright DG, Malawista SE. Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylates. Arthritis Rheum. 1973;16:749–58.
Ben-Chetrit E, Fischel R, Hinz B, Levy M. The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2. Rheumatol Int. 2005;25:332–5.
Chappey ON, Niel E, Wautier JL, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther. 1993;54:360–7.
Ertel NH, Wallace SL. Measurement of colchicine in urine and peripheral leukocytes. Clin Res. 1971;19:3480.
Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses. 1998;51(5):377–80.
Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83:2451–587.
Abedat S, Urieli-Shoval S, Shapira E, Calko S, Ben-Chetrit E, Matzner Y. Effect of colchicine and cytokines on MEFV expression and C5a inhibitor activity in human primary fibroblast cultures. Isr Med Assoc J. 2002;4(1):7–12.
Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, Gumucio DL, Shoham NG, Kastner DL. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112:1794–803.
Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, Akkaya YZ, Yilmaz E. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem. 2012;113(11):3536–46.
Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford). 2006;45(3):274–82. Epub 2005.
Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013;14:454–60.
Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314(16):1001–5.
Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron. 1992;60(4):418–22.
Migita K, Uehara R, Nakamura Y, Yasunami M, Tsuchiya-Suzuki A, Yazaki M, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore). 2012;91:337–43.
Hentgen V, Kone-Paut GGI, Livneh A, Padeh S, Rozenbaum M, Amselem S, Gershoni-Baruch R, Touitou I, Ben-Chetrit E. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013;43:387–91.
Tunca M, Turkish FMF Study Group, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1–11.
Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659–64.
Lidar M, Kedem R, Langevitz P, Pras M, Livneh A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol. 2003;30:2620–3.
Tankurt E, Tunca M, Akbaylar H, Gonen O. Resolving familial Mediterranean fever attacks with interferon alpha. Br J Rheumatol. 1996;35:1188–9.
Tunca M, Tankurt E, Akbaylar Akpinar H, Akar S, Hizli N, Gonen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol. 1997;36:1005–8.
Calguneri M, Apras S, Ozturk MA, Ertenli I, Kiraz S. The efficacy of the interferon alfa on colchicine resistant familial Mediterranean fever (FMF). Clin Exp Rheumatol. 2002;20:S106. Abstract.
Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever, a double blind and placebo controlled trial. Clin Exp Rheumatol. 2004;22 Suppl 34:S37–40.
Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol. 2002;20(4 Suppl 26):S43–4.
Drenth JP, Vonk AG, Simon A, et al. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper IgD and periodic fever syndromes: a double-blind, placebo-controlled trial. J Pharmacol Exp Ther. 2001;298:1221–6.
Erken E, Ozer HT, Bozkurt B, Gunesacar R, Erken EG, Dinkci S. Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Joint Bone Spine. 2008;75:370–2.
Amital H, Ben-Chetrit E. Therapeutic approaches to familial Mediterranean fever. What do we know and where are we going to? Clin Exp Rheumatol. 2004;22 Suppl 34:S4–7.
Korkmaz C. Immunosuppressive treatment of AA amyloidosis of familial Mediterranean fever. Clin Exp Rheumatol. 2005;23 Suppl 38:S107–8.
Sayarlioglu H. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int. 2006;27(2):197–9.
Milledge J, Shaw PJ, Mansour A, Williamson S, Bennetts B, Roscioli T, Curtin J, Christodoulou J. Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. Blood. 2002;100:774–7.
Touitou I, Ben-Chetrit E, Gershoni-Baruch R, et al. Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever. Blood. 2003;102:409.
Taylor EW. Mechanism of colchicine inhibition of mitosis I. Kinetics of inhibition and the binding of H3-colchicine. J Cell Biol. 1965;25(1):145–60.
Merlin HE. Azoospermia caused by colchicine – a case report. Fertil Steril. 1972;23:180–1.
Barsou IS. The effect of colchicine on the spermatogenesis of rabbits. J Pharmacol Exp Ther. 1955;113:319–22.
Cohen MM, Levy M, Eliakim M. A cytogenetic evaluation of long-term colchicine therapy in the treatment of familial Mediterranean fever (FMF). Am J Med Sci. 1977;274:147–52.
Levy M, Yaffe C. Testicular function in patients with familial Mediterranean fever, on long-term colchicine treatment. Fertil Steril. 1978;29:662–8.
Ehrenfeld M, Levy M, Margalioth EJ, Eliakim M. The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever. Andrologia. 1986;13:420–6.
Ben-Chetrit A, Ben-Chetrit E, Nitzan R, Ron M. Colchicine inhibits spermatozoal motility in vitro. Int J Fertil. 1993;38:301–4.
Bremner WJ, Paulson CA. Colchicine and testicular function in man. N Engl J Med. 1976;294:1384–5.
Sarica K, Suzer O, Gurler A, Baltaci S, Ozdiler E, Dincel C. Urological evaluation of Behcet’s patients and the effect of colchicine on fertility. Eur J Mol. 1995;22:39–42.
Haimov-Kochman R, Prus D, Ben-Chetrit E. Azoospermia due to testicular amyloidosis in a patient with familial Mediterranean fever. Hum Reprod. 2001;16:1218–20.
Zemer TD, Pras M, Shemer Y. Daily prophylactic colchicine in familial Mediterranean fever amyloid and amyloidosis. Proceedings of the 3rd International Symposium on Amyloidosis, Exerpta Medica, Amsterdam-Oxford-Prinston; 1980. p. 580
Ben-Chetrit E, Berkun Y, Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial Mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34:549–52.
Schwartz J. Periodic peritonitis, onset simultaneously with menstruation. Ann Intern Med. 1960;53:407–11.
Golden RL, Weigers EW, Meagher JG. Periodic fever and menses. Am J Obstet Gynecol. 1973;117:855–6.
Milano AM. Familial Mediterranean fever associated with menstruation. Am J Gastroenterol. 1981;76:363–4.
Ben-Chetrit E, Ben-Chetrit A. Familial Mediterranean fever and menstruation. Br J Obstet Gynecol. 2001;108:403–7.
Koh KK, Bui MN, Mincemoyer R, Cannon RO. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol. 1997;80:1505–7.
Chaudoreille MM, Peyrot V, Braguer D, Codaccioni F, Crevat A. Qualitative study of the interaction mechanism of estrogenic drugs with tubulin. Biochem Pharmacol. 1991;41:685–93.
Tanchev S, Papov I, Tomov S. A rare combination of pregnancy and periodic disease treated with colchicine. Akush Gynecol Sofiia. 1993;32:41–2.
Cousin C, Palaric JC, Jacquemand F, Lucas S, Girard JR. Periodic disease and pregnancy. J Gynecol Obstet Biol Reprod Paris. 1991;20:554–61.
Ehrenfeld M, Bzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynecol. 1987;94:1186–91.
Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991;20:241–6.
Granat M, Tur Kaspa I, Zylber-Katz E, Schenker JG. Reduction of peritoneal adhesion formation by colchicine: a comparative study in the rat. Fertil Steril. 1983;40:369–72.
Rabinovitch O, Zemer D, Kurkia E, Sohar E, Mashiach S. Colchicine treatment in conception and pregnancy: two hundred and thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol. 1992;28:245–6.
Berkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barkai G. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193:1513–6.
Ben-Chetrit E, Ben-Chetrit A, Berkun Y. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res. 2010;62:143–8.
Ofir D, Levy A, Wiznitzer A, Mazor M, Sheiner E. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2008;141:115–8.
Diav-Citrin O, Shechtman S, Schwartz V, Avgil-Tsadok M, Finkel-Pekarsky V, Wajnberg R, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203:144.e1–6.
Briggs GG, Freeman RK, Yaffe RS. Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams & Wilkins; 1994.
Milunsky JM, Milunsky A. Breast feeding during colchicine therapy for familial Mediterranean fever. J Pediatr. 1991;119:163.
Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39:1213–7.
Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34:973–7.
Maged HM, Carroll JE, Khuffash FA, Hijazi Z. Long-term colchicine prophylaxis in children with familial Mediterranean fever (recurrent hereditary polyserositis). J Pediatr. 1990;116:997–9.
Savgan-Gürol E, Kasapçopur Ö, Hatemi S, Ercan O, Çaliskan S, Sever L, Özdogan H, Arisoy N. Growth and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment. Clin Exp Rheumatol. 2001;19 Suppl 24:S72–5.
Slopa EG, O’Brien R, Katz M. Effect of colchicine on guinea pig intrinsic factor vitamin B12 receptor. Gastroenterology. 1979;26:309–14.
Fradkin A, Yahav J, Zemer D, Jonas A. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci. 1995;31:616–20.
Hart J, Lewin KJ, Peters RS, Scher AD. Effect of long-term colchicine therapy on jejunal mucosa. Dig Dis Sci. 1993;38:2017–21.
Desmond PV, Patwardhan RV, Parker R, Schenker S, Speeg KV. Effect of cimetidine and other antihistaminics on the elimination of aminopyrine phenacetin and caffeine. Life Sci. 1989;26:1261–8.
Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Matthew W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–37.
Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication clinical pharmacology, risk factors, features and management. Semin Arthritis Rheum. 1991;21:143–55.
Macleod G, Phillips L. Hypersensitivity to colchicine. Ann Rheum Bis. 1947;6:224–9.
Jarevic D, Park J, Steward MJ. Estimation of colchicine in a poisoned patient by using high performance liquid chromatography. Clin Toxicol. 1979;14:375–81.
Nadius RB, Rodvien R, Mielke CH. Colchicine toxicity: a multisystem disease. Arch Intern Med. 1977;127:394–6.
Baud FJ, Sabourand A, Vicente E, Taboulet P, Lang J, Bismuth C. Treatment of severe colchicine overdose with colchicine specific fab fragments. N Engl J Med. 1995;332:642–5.
Blankestijn PJ, Vos FP. High flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol. 1995;5:1703–7.
Ben-Chetrit E, Backenroth R, Levy M. Colchicine clearance by high-flux polysulfone dialyzers. Arthritis Rheum. 1998;41:749–50.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ben-Chetrit, E. (2015). How to Manage Familial Mediterranean Fever (FMF) Patients in Daily Practice. In: Gattorno, M. (eds) Familial Mediterranean Fever. Rare Diseases of the Immune System, vol 3. Springer, Cham. https://doi.org/10.1007/978-3-319-14615-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-14615-7_8
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14614-0
Online ISBN: 978-3-319-14615-7
eBook Packages: MedicineMedicine (R0)